NCT03630042 · OUTCOME

Time to Maximal Response as Determined by the Time of Registration to the Maximal Disease Response

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia · Source last updated 2024-11-07

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Assessed at 12 weeks, 24 weeks and 1 year after commencing treatment

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
reporting Status: NOT_POSTED
time Frame: Assessed at 12 weeks, 24 weeks and 1 year after commencing treatment
title: Time to Maximal Response as Determined by the Time of Registration to the Maximal Disease Response
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice